AZD 6942Alternative Names: CCR2b
Latest Information Update: 03 Dec 2001
At a glance
- Originator AstraZeneca
- Class Antirheumatics
- Mechanism of Action CCR2 receptor antagonists; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 03 Dec 2001 Discontinued - Clinical-Phase-Unknown for Rheumatoid arthritis in Sweden (unspecified route)
- 20 Sep 2001 New profile
- 20 Sep 2001 Investigation in Rheumatoid arthritis in Sweden (Unknown route)